AB196025

Anti-KRIT1 抗体 [EPR16560]

Name: Anti-KRIT1 抗体 [EPR16560] (ab196025) | Abcam
Brand: Abcam Limited
SKU: AB196025
Price: 45000 JPY
Availability: InStock
Rating: 5 (3 reviews)

Anti-KRIT1 antibody [EPR16560]

RabMAb
Recombinant
詳細を見る

(3 Reviews)

(11 Publications)

Rabbit Recombinant Monoclonal KRIT1 antibody. Suitable for WB, ICC/IF and reacts with Mouse, Human samples. Cited in 11 publications.

別名を表示する

CCM1, KRIT1, Krev interaction trapped protein 1, Krev interaction trapped 1, Cerebral cavernous malformations 1 protein

4 Images

Immunocytochemistry/ Immunofluorescence - Anti-KRIT1 antibody [EPR16560] (AB196025)

ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-KRIT1 antibody [EPR16560] (AB196025)

Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HUVEC (Human umbilical vein endothelial cell line) cells labeling KRIT1 with ab196025 at 1/100 dilution, followed by Goat anti-rabbit IgG (Alexa Fluor® 488) (ab150077) secondary antibody at 1/500 dilution (green). Cytoplasm staining on HUVEC cell line is observed. The nuclear counter stain is DAPI (blue). Tubulin is detected with ab7291 (anti-Tubulin mouse mAb) at 1/1000 dilution and ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/500 dilution (red).
The negative controls are as follows :
-ve control 1 : ab196025 at 1/100 dilution followed by ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/500 dilution.
-ve control 2 : ab7291 (anti-Tubulin mouse mAb) at 1/1000 dilution followed by ab150077 (Alexa Fluor®488 Goat Anti-Rabbit IgG H&L) at 1/500 dilution.

Supplier Data

Western blot - Anti-KRIT1 antibody [EPR16560] (AB196025)

Blocking/Dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-KRIT1 antibody [EPR16560] (ab196025) at 1/5000 dilution

All lanes:

HUVEC (Human umbilical vein endothelial cell line) whole cell lysate at 10 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

Predicted band size: 84 kDa

Observed band size: 84 kDa

false

Supplier Data

Western blot - Anti-KRIT1 antibody [EPR16560] (AB196025)

Blocking/Dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-KRIT1 antibody [EPR16560] (ab196025) at 1/5000 dilution

Lane 1:

Human fetal brain lysate at 20 µg

Lane 2:

SH-SY5Y (Human neuroblastoma from bone marrow cells) cell lysate at 20 µg

Lane 3:

Raji (Human Burkitt's lymphoma cell line) cell lysate at 20 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

Predicted band size: 84 kDa

Observed band size: 84 kDa

false

Supplier Data

Western blot - Anti-KRIT1 antibody [EPR16560] (AB196025)

Blocking/Dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-KRIT1 antibody [EPR16560] (ab196025) at 1/1000 dilution

Lane 1:

Mouse brain lysate at 10 µg

Lane 2:

NIH/3T3 (Mouse embyro fibroblast cells) cell lysate at 10 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

Predicted band size: 84 kDa

Observed band size: 84 kDa

false

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EPR16560

アイソタイプ

IgG

キャリアフリー

交差種

Mouse, Human

アプリケーション

ICC/IF, WB

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/100", "ICCIF-species-notes": "" }, "Mouse": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

style

left-column

製品の詳細

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

出荷温度及び保存条件

製品の状態

Liquid

精製方法

Affinity purification Protein A

バッファー組成

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

出荷温度

Conditional Ambient

短期保存期間

1-2 weeks

短期保存温度

+4°C

長期保存温度

-20°C

分注に関する情報

Upon delivery aliquot

保管に関する情報

Avoid freeze / thaw cycle

style

left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

KRIT1 also known as Krev interaction trapped 1 and CCM1 is a protein encoded by the KRIT1 gene. This protein has a mass of approximately 99 kilodaltons. Mechanically KRIT1 functions as an adapter protein interacting with several molecular partners to regulate cellular processes. KRIT1 is expressed broadly in various tissues including in the endothelial cells of blood vessels.

Biological function summary

This protein is involved in the maintenance of vascular integrity and formation. It forms a complex with other proteins like CCM2 and PDCD10 playing a critical role in stabilizing cell-cell junctions. By organizing junctional proteins KRIT1 supports cellular architecture and mechanotransduction. This action ensures proper response to hemodynamic forces within blood vessels.

Pathways

KRIT1 is involved in the RhoA signaling pathway and integrin-dependent pathways. In the RhoA signaling pathway KRIT1 interacts with HEG1 and MAPK to facilitate signal transduction that influences cell shape and movement. Through the integrin-dependent pathway KRIT1 regulates integrins essential for cell adhesion and migration. This regulation highlights its role in mechanotransduction and vascular stability.

KRIT1 mutations associate with cerebral cavernous malformations (CCM) a condition characterized by vascular lesions in the brain. These mutations disrupt interactions with CCM2 affecting vascular development and stability. KRIT1 has connections to other cerebrovascular-related proteins indicating its involvement in leaky blood vessels that form lesions. Understanding KRIT1's interaction pathways is key to developing therapies for CCM and potentially related vascular disorders.

style

left-column

style

left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

ターゲットの情報

Component of the CCM signaling pathway which is a crucial regulator of heart and vessel formation and integrity (By similarity). Negative regulator of angiogenesis. Inhibits endothelial proliferation, apoptosis, migration, lumen formation and sprouting angiogenesis in primary endothelial cells. Promotes AKT phosphorylation in a NOTCH-dependent and independent manner, and inhibits ERK1/2 phosphorylation indirectly through activation of the DELTA-NOTCH cascade. Acts in concert with CDH5 to establish and maintain correct endothelial cell polarity and vascular lumen and these effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction, and cell junction stabilization. Plays a role in integrin signaling via its interaction with ITGB1BP1; this prevents the interaction between ITGB1 and ITGB1BP1. Microtubule-associated protein that binds to phosphatidylinositol 4,5-bisphosphate (PIP2)-containing membranes in a GTP-bound RAP1-dependent manner. Plays an important role in the maintenance of the intracellular reactive oxygen species (ROS) homeostasis to prevent oxidative cellular damage. Regulates the homeostasis of intracellular ROS through an antioxidant pathway involving FOXO1 and SOD2. Facilitates the down-regulation of cyclin-D1 (CCND1) levels required for cell transition from proliferative growth to quiescence by preventing the accumulation of intracellular ROS through the modulation of FOXO1 and SOD2 levels. May play a role in the regulation of macroautophagy through the down-regulation of the mTOR pathway (PubMed : 26417067).

See full target information KRIT1

style

left-column

文献 (11)

Recent publications for all applications. Explore the full list and refine your search

The Journal of cell biology 223: PubMed39013281

2024

TLNRD1 is a CCM complex component and regulates endothelial barrier integrity.

Applications

Unspecified application

Species

Unspecified reactive species

Neil J Ball,Sujan Ghimire,Gautier Follain,Ada O Pajari,Diana Wurzinger,Monika Vaitkevičiūtė,Alana R Cowell,Bence Berki,Johanna Ivaska,Ilkka Paatero,Benjamin T Goult,Guillaume Jacquemet

APL bioengineering 8:016108 PubMed38352162

2024

Hyaluronic acid turnover controls the severity of cerebral cavernous malformations in bioengineered human micro-vessels.

Applications

Unspecified application

Species

Unspecified reactive species

Teodor E Yordanov,Mikaela S Keyser,Marco A Enriquez Martinez,Tyron Esposito,Juliann B Tefft,Elysse K Morris,Larisa I Labzin,Samantha J Stehbens,Alan E Rowan,Benjamin M Hogan,Christopher S Chen,Jan Lauko,Anne K Lagendijk

Circulation 149:1183-1201 PubMed38099436

2023

HEG1 Protects Against Atherosclerosis by Regulating Stable Flow-Induced KLF2/4 Expression in Endothelial Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Ian A Tamargo,Kyung In Baek,Chenbo Xu,Dong Won Kang,Yerin Kim,Aitor Andueza,Darian Williams,Catherine Demos,Nicolas Villa-Roel,Sandeep Kumar,Christian Park,Rachel Choi,Janie Johnson,Seowon Chang,Paul Kim,Sheryl Tan,Kiyoung Jeong,Shoutaro Tsuji,Hanjoong Jo

Biomedicines 11: PubMed36831015

2023

Multidrug-Loaded Lipid Nanoemulsions for the Combinatorial Treatment of Cerebral Cavernous Malformation Disease.

Applications

Unspecified application

Species

Unspecified reactive species

Andrea Perrelli,Annalisa Bozza,Chiara Ferraris,Sara Osella,Andrea Moglia,Silvia Mioletti,Luigi Battaglia,Saverio Francesco Retta

Biomaterials science 8:5133-5144 PubMed32821891

2020

NIR-II window tracking of hyperglycemia induced intracerebral hemorrhage in cerebral cavernous malformation deficient mice.

Applications

Unspecified application

Species

Unspecified reactive species

Abdul K Parchur,Zhi Fang,Jaidip M Jagtap,Gayatri Sharma,Christopher Hansen,Shayan Shafiee,Wenquan Hu,Qing R Miao,Amit Joshi

Methods in molecular biology (Clifton, N.J.) 2152:131-137 PubMed32524549

2020

Generation of CCM Phenotype by a Human Microvascular Endothelial Model.

Applications

Unspecified application

Species

Unspecified reactive species

Simona Delle Monache,Saverio Francesco Retta

Methods in molecular biology (Clifton, N.J.) 2152:151-167 PubMed32524551

2020

Production of KRIT1-knockout and KRIT1-knockin Mouse Embryonic Fibroblasts as Cellular Models of CCM Disease.

Applications

Unspecified application

Species

Unspecified reactive species

Luca Goitre,Claudia Fornelli,Alessia Zotta,Andrea Perrelli,Saverio Francesco Retta

Antioxidants (Basel, Switzerland) 8: PubMed30658464

2019

KRIT1 Loss-Of-Function Associated with Cerebral Cavernous Malformation Disease Leads to Enhanced -Glutathionylation of Distinct Structural and Regulatory Proteins.

Applications

Unspecified application

Species

Unspecified reactive species

Laura Cianfruglia,Andrea Perrelli,Claudia Fornelli,Alessandro Magini,Stefania Gorbi,Anna Maria Salzano,Cinzia Antognelli,Francesca Retta,Valerio Benedetti,Paola Cassoni,Carla Emiliani,Giovanni Principato,Andrea Scaloni,Tatiana Armeni,Saverio Francesco Retta

ACS omega 3:15389-15398 PubMed30556006

2018

Multifunctional Platinum@BSA-Rapamycin Nanocarriers for the Combinatorial Therapy of Cerebral Cavernous Malformation.

Applications

Unspecified application

Species

Unspecified reactive species

Elisa De Luca,Deborah Pedone,Mauro Moglianetti,Daniele Pulcini,Andrea Perrelli,Saverio Francesco Retta,Pier Paolo Pompa

Human mutation 39:1885-1900 PubMed30161288

2018

A single-center study on 140 patients with cerebral cavernous malformations: 28 new pathogenic variants and functional characterization of a PDCD10 large deletion.

Applications

Unspecified application

Species

Unspecified reactive species

Grazia Nardella,Grazia Visci,Vito Guarnieri,Stefano Castellana,Tommaso Biagini,Luigi Bisceglia,Orazio Palumbo,Marina Trivisano,Carmela Vaira,Massimo Scerrati,Davide Debrasi,Vincenzo D'Angelo,Massimo Carella,Giuseppe Merla,Tommaso Mazza,Marco Castori,Leonardo D'Agruma,Carmela Fusco

View all publications

style

left-column

style

left-column

style

right-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。

保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-KRIT1 抗体 [EPR16560]

Anti-KRIT1 antibody [EPR16560]

Immunocytochemistry/ Immunofluorescence - Anti-KRIT1 antibody [EPR16560] (AB196025)

Western blot - Anti-KRIT1 antibody [EPR16560] (AB196025)

Western blot - Anti-KRIT1 antibody [EPR16560] (AB196025)

Western blot - Anti-KRIT1 antibody [EPR16560] (AB196025)

関連する標識済み抗体及び組成の異なる製品 (1)

Key facts

宿主種

クローン性

クローン番号

アイソタイプ

キャリアフリー

交差種

アプリケーション

免疫原

組合せ製品

Primary Antibodies

Reagents, Controls & Accessories

Primary Antibodies

Primary Antibodies

Reactivity data

製品の詳細

出荷温度及び保存条件

製品の状態

精製方法

バッファー組成

出荷温度

短期保存期間

短期保存温度

長期保存温度

分注に関する情報

保管に関する情報

補足情報

Biological function summary

Pathways

製品プロトコール

ターゲットの情報

文献 (11)

Abcam product promise